TMDX TransMedics
- 127.990
- +3.550+2.85%
- 128.520
- +0.530+0.41%
TransMedics News
Canadian Investment Banking Group: Maintaining the TransMedics Gr (TMDX.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $102.00 to $117.00.
Canaccord Genuity Maintains Buy on TransMedics Gr, Raises Price Target to $117
TransMedics Group (TMDX) Receives a Buy From Piper Sandler
Oppenheimer: Maintaining the TransMedics Gr (TMDX.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $105.00 to $125.00.
TransMedics Gr Analyst Ratings
Oppenheimer Maintains Outperform on TransMedics Gr, Raises Price Target to $125
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
TransMedics Gr Analyst Ratings
TransMedics Group: Operational Efficiency and Market Positioning Propel Buy Rating
Damo: Maintaining the TransMedics Gr (TMDX.US) shareholding rating, the target price was adjusted from $75.00 to $95.00.
Morgan Stanley Maintains Equal-Weight on TransMedics Gr, Raises Price Target to $95
Oppenheimer Adjusts TransMedics Group Price Target to $105 From $92, Maintains Outperform Rating
Oppenheimer Sticks to Its Buy Rating for TransMedics Group (TMDX)
TransMedics Gr Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), TransMedics Group (TMDX) and MoonLake Immunotherapeutics (MLTX)
Buy Rating on TransMedics Group Amidst Growing Organ Transplant Market
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tecan Group AG (OtherTCHBF), TransMedics Group (TMDX) and Argenx Se (ARGX)
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), TransMedics Group (TMDX) and Apellis Pharmaceuticals (APLS)
TransMedics Gr Analyst Ratings
Morgan Stanley Adjusts TransMedics Group Price Target to $75 From $54, Maintains Equal Weight Rating
Analysis
Price Target
No Data
